Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas

This study has been completed.
Sponsor:
Collaborators:
McGill University
Asociacion Civil Selva Amazonica
World Health Organization
Thrasher Research Fund
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Dr. Theresa Gyorkos, McGill University Health Center
ClinicalTrials.gov Identifier:
NCT01314937
First received: March 11, 2011
Last updated: August 25, 2014
Last verified: August 2014
  Purpose

Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two.

Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.


Condition Intervention Phase
Malnutrition
Intestinal Diseases, Parasitic
Drug: Mebendazole
Other: Usual care
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care

Resource links provided by NLM:


Further study details as provided by McGill University Health Center:

Primary Outcome Measures:
  • Mean (± standard deviation) weight gain (kg) [ Time Frame: from 12 to 24 months of age ] [ Designated as safety issue: No ]
    Weight will be measured at baseline (12 months of age), and follow-up (18 and 24 months of age) to assess the effect of the deworming intervention on growth (in terms of weight)


Secondary Outcome Measures:
  • Mean (± standard deviation) height gain (cm) [ Time Frame: from 12 to 24 months of age ] [ Designated as safety issue: No ]
    Height will be measured at baseline (12 months of age) and at follow-up (18 and 24 months of age) to evaluate the effect of the deworming intervention on growth (in terms of height)

  • Mean (± standard deviation) of the cognitive test score [ Time Frame: from 12 to 24 months of age ] [ Designated as safety issue: No ]
    Cognitive development will be assessed using the Bayley Scale of Infant Development. This scale provides a raw score and standardized score based on age-specific abilities. This will be measured at both baseline (12 months of age) and follow-up (at 24 months of age) to evaluate the effects of the deworming intervention on cognitive development.

  • Soil-transmitted helminth infection (Ascaris, Trichuris or hookworm) - prevalence (%) and intensity (mean eggs per gram) [ Time Frame: from 12 to 24 months of age ] [ Designated as safety issue: No ]
    Soil-transmitted helminth (STH) infection will be assessed from stool samples provided by participants. The Kato-Katz technique will be used to provide both an estimate of prevalence of each STH (e.g. % positive for each Ascaris, Trichuris, and/or hookworm) as well as an estimate of intensity of each STH (measured as mean eggs per gram of stool). This will be measured at baseline (12 months of age) and follow-up (18 and 24 months of age) to evaluate the effect of the deworming intervention on parasite prevalence and intensity.

  • Mean (± standard deviation) of the motor test score [ Time Frame: from 12 to 24 months of age ] [ Designated as safety issue: No ]
    Fine motor development will be assessed using the Bayley Scale of Infant Development. This scale provides a raw score and standardized score based on age-specific abilities. This will be measured at both baseline (12 months of age) and follow-up (at 24 months of age) to evaluate the effects of the deworming intervention on motor development.

  • Mean (± standard deviation) of the language test score [ Time Frame: from 12 to 24 months of age ] [ Designated as safety issue: No ]
    Receptive and expressive language development will be assessed using the Bayley Scale of Infant Development. This scale provides a raw score and standardized score based on age-specific abilities. This will be measured at both baseline (12 months of age) and follow-up (at 24 months of age) to evaluate the effects of the deworming intervention on language development.


Estimated Enrollment: 1760
Study Start Date: September 2011
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Deworming at 12 months of age Drug: Mebendazole
Single-dose 500 mg mebendazole tablet
Other Name: Vermox, Nemasole, Pantelmin
Other: Usual care
Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
Other Name: Standard of care, routine health care services
Experimental: Deworming at 18 months of age Drug: Mebendazole
Single-dose 500 mg mebendazole tablet
Other Name: Vermox, Nemasole, Pantelmin
Other: Usual care
Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
Other Name: Standard of care, routine health care services
Experimental: Deworming at 12 and 18 months of age Drug: Mebendazole
Single-dose 500 mg mebendazole tablet
Other Name: Vermox, Nemasole, Pantelmin
Other: Usual care
Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
Other Name: Standard of care, routine health care services
Placebo Comparator: Usual care Other: Usual care
Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
Other Name: Standard of care, routine health care services

Detailed Description:

Worldwide, over 2 billion people suffer from worm infections (hookworm, Ascaris and Trichuris, collectively referred to as soil-transmitted helminths (STHs)) in developing countries. STHs contribute to the overwhelming burden of poverty and deprivation in areas where adverse health, social, economic, education and other related factors predominate. STH infection in childhood results in short-term and lifelong disability, including malnutrition (e.g. underweight, stunting and wasting), cognitive impairment and increased susceptibility to other infection, among others. Mass deworming programs in school-age children are recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool children (as of 12 months of age) in endemic areas; however, the benefits of deworming on improving growth and development, especially in the 12-24 month age group, have been inadequately studied. This knowledge is crucial because, with appropriate nutrition and health interventions, all children have a similar potential for healthy growth and development, provided that such interventions occur in the critical window of opportunity before the age of two.

Therefore, this double-blind randomized controlled trial will assess the benefit of deworming (mebendazole), integrated into routine child health care visits in a highly STH-endemic area (Iquitos, Peru), on the primary outcome of weight gain. Timing, frequency and impact of deworming will be considered. A total of 1760 children will be recruited at their routine 12-month check-up visit and randomly assigned to one of four intervention groups: Group 1 will receive usual care and mebendazole (single dose 500 mg) at their 12-month visit and usual care and a placebo tablet at their 18-month visit; Group 2 will receive usual care and a placebo tablet at their 12-month visit and usual care and mebendazole at their 18-month visit; Group 3 will receive usual care and mebendazole at both their 12-month and 18-month visit; and Group 4 will receive usual care and placebo at both their 12-month and 18-month visit. Usual care will consist of age-appropriate immunizations, supplements and other Peruvian Ministry of Health-recommended interventions. All children will be followed up to their 24-month visit and all will be given mebendazole at that time.

Additional secondary outcomes include length gain, motor and cognitive development and STH prevalence and intensity.

Improving child health is a priority area in global health research and a focus of the Millennium Development Goals. Early preschool-age children are at the most critical stage of growth and development and have been neglected in deworming programs. It is anticipated that the results will inform evidence-based policy on the provision of an integrated health package for young children in endemic areas and ultimately contribute to the reduction of health inequities in this vulnerable group.

  Eligibility

Ages Eligible for Study:   12 Months to 24 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • children attending any one of the participating study health centres for their routine 12-month growth and development visit
  • children living in or near the study area

Exclusion Criteria:

  • children who are attending the clinic for suspected STH infection
  • children who have received deworming treatment in the six months prior to randomization
  • parents planning to move outside of the study area within the next 12 months
  • children under 12 months of age or 14 months of age or older
  • children with serious congenital or chronic medical conditions and who would be considered by the attending staff not to benefit from deworming
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01314937

Locations
Peru
Asociacion Civil Selva Amazonica
Iquitos, Loreto, Peru
Sponsors and Collaborators
McGill University Health Center
McGill University
Asociacion Civil Selva Amazonica
World Health Organization
Thrasher Research Fund
Canadian Institutes of Health Research (CIHR)
Investigators
Principal Investigator: Theresa W Gyorkos, PhD McGill University
Principal Investigator: Martin Casapia, MD, MPH Asociacion Civil Selva Amazonica
  More Information

No publications provided

Responsible Party: Dr. Theresa Gyorkos, Principal Investigator, McGill University Health Center
ClinicalTrials.gov Identifier: NCT01314937     History of Changes
Other Study ID Numbers: 10-242-PED
Study First Received: March 11, 2011
Last Updated: August 25, 2014
Health Authority: Canada: Ethics Review Committee
Peru: Ethics Committee
Peru: Instituto Nacional de Salud

Keywords provided by McGill University Health Center:
preschool-age children
soil-transmitted helminths
growth
development
deworming

Additional relevant MeSH terms:
Intestinal Diseases
Intestinal Diseases, Parasitic
Malnutrition
Nutrition Disorders
Parasitic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Mebendazole
Anthelmintics
Anti-Infective Agents
Antimitotic Agents
Antinematodal Agents
Antineoplastic Agents
Antiparasitic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on November 25, 2014